About Walking Fish Therapeutics
Walking Fish Therapeutics is a Healthcare company based in San Francisco (United States) founded in 2019 by Seenu Kothakota, Lewis T Williams, Mark Selby, and Tom Brennan. Cell-based therapeutics for cancer and immunological disorders are developed. Walking Fish Therapeutics has raised $123 million across 2 funding rounds from investors including Northpond Ventures, First Spark Ventures and TMCP. Its chief executive, as recorded, is Lewis T Williams. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and Diversified. Its legal entity is Walking Fish Therapeutics, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Walking Fish Therapeutics was founded in 2019 in San Francisco, United States, within the biotechnology sector. Cell-based solutions are developed to address cancer and immunological disorders. Proprietary technology based on B cells and their derivatives is used to generate therapeutic proteins, including antibodies for infectious diseases, replacement proteins for deficiencies, immune-inhibitory proteins for autoimmune conditions, and regenerative proteins. Antigens are supplied to support antitumor immune responses in oncology applications.
- Headquarters San Francisco, United States
- Founders Seenu Kothakota, Lewis T Williams, Mark Selby, Tom Brennan
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website walkingfishtx.com
- Social LinkedIn X
- Legal Name Walking Fish Therapeutics, Inc.
- Total Equity Funding$123M (USD)
in 2 rounds
- Latest Funding Round$73M (USD), Series A
Feb 2022
- InvestorsNorthpond Ventures
& 5 more
Funding Insights of Walking Fish Therapeutics
Walking Fish Therapeutics has successfully raised a total of $123M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $73 million completed in February 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $123M
- Total Rounds 2
- Last Round Series A — $73M
- First Round $50M
(Sep 2021)
- Investors Count 6
All 2 funding rounds of Walking Fish Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2022 | $73M | Series A | – | Northpond Ventures, First Spark Ventures | |
| Sep 2021 | $50M | Series A | – | Emerson Collective, Illumina Ventures | – |
6 investors in total: 6 institutional.
Investors in Walking Fish Therapeutics
Walking Fish Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Northpond Ventures, First Spark Ventures and TMCP.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
A venture capital fund focused on deep tech innovations is managed. | firstsparkventures.com | |||
Private equity investments in China are managed by TMCP. | terramagnumcap.com | Chaoyang, China | ||
Health tech startups are invested in by Illumina Ventures. | illuminaventures.com | Foster City, United States | ||
Investments are directed toward early and growth stage companies. | quancapital.com | Pudong, China | ||
| emersoncollective.com |
Investor details for Walking Fish Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Walking Fish Therapeutics
4 people are tracked at Walking Fish Therapeutics (4 in leadership).
| Name | Role | Group |
|---|---|---|
Seenu Kothakota | Co-Founder | Leadership |
Lewis T Williams | Co-Founder & CEO | Leadership |
Mark Selby | Co-Founder | Leadership |
Tom Brennan | Co-Founder | Leadership |
Complete people profiles for Walking Fish Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Walking Fish Therapeutics
3 dated milestones of Walking Fish Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Walking Fish Therapeutics is founded.
- Funding First funding round of $50.0M.
- Funding Latest funding round, Series A, of $73.0M.
Competitors of Walking Fish Therapeutics
Walking Fish Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Walking Fish Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Walking Fish Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Walking Fish Therapeutics
Complete news archive for Walking Fish Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Walking Fish Therapeutics
Walking Fish Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Walking Fish Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Lewis T Williams is the CEO of Walking Fish Therapeutics, as recorded in our data. They have also founded this company.
Walking Fish Therapeutics is a funded company, having raised a total of $123M across 2 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Sep 2021.
Walking Fish Therapeutics was founded in 2019 in San Francisco, United States, within the biotechnology sector. Cell-based solutions are developed to address cancer and immunological disorders. Proprietary technology based on B cells and their derivatives is used to generate therapeutic proteins, including antibodies for infectious diseases, replacement proteins for deficiencies, immune-inhibitory proteins for autoimmune conditions, and regenerative proteins. Antigens are supplied to support antitumor immune responses in oncology applications.
Walking Fish Therapeutics has 6 investors. Key investors include Northpond Ventures, First Spark Ventures, TMCP, Emerson Collective, and Illumina Ventures.
Walking Fish Therapeutics operates through Walking Fish Therapeutics, Inc..